v3.25.2
Fair Value of Financial Assets and Liabilities (Tables)
 6 Months Ended
Jul. 31, 2025
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.
 July 31, 2025
(in thousands)Level 1 Level 2 Level 3
Assets
Cash equivalents:
Money market funds$76,923 $— $— 
Restricted cash equivalents: money market funds11,662 — — 
Short-term investments:
U.S. Treasury securities22,608 $— $— 
Commercial paper— 2,189 $— 
Corporate bonds— 64,491 $— 
Certificates of deposit— 1,162 $— 
Total assets$111,193 $67,842 $— 
Liabilities
Public Warrants$8,564 $— $— 
Private Placement Warrants— $— 4,806 
Contingent consideration for acquisitions— $— 3,414 
Total liabilities$8,564 $— $8,220 
 January 31, 2025
(in thousands)Level 1Level 2Level 3
Assets
Cash equivalents:
Money market funds$29,054 $— $— 
Restricted cash equivalents: money market funds10,350——
Short-term investments:
U.S. Treasury securities13,095——
Commercial paper—4,290—
Corporate bonds—84,528—
Certificates of deposit—2,114—
Total assets$52,499 $90,932 $— 
Liabilities
Public Warrants$9,177 $— $— 
Private Placement Warrants——8,900
Contingent consideration for acquisitions— — 7,558 
Total liabilities$9,177 $— $16,458 
Schedule of Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The following is a roll-forward of Level 3 liabilities measured at fair value for the three and six months ended July 31, 2025 and 2024:
(in thousands)Private Placement Warrants
Technical Milestone Contingent Consideration (1)
Customer Contract Earnout Contingent Consideration (1)
Customer Consent Escrow Contingent Consideration (1)
Fair value at end of year, January 31, 2024$1,305 $5,114 $1,926 $5,851 
Payments——(180)—
Change in fair value(771)(183)1369
Fair value at April 30, 2024$534 $4,931 $1,759 $5,920 
Payments——(1,090)—
Change in fair value3265791551,291
Fair value at July 31, 2024$860 $5,510 $824 $7,211 
Fair value at end of year, January 31, 2025$8,900 $5,980 $1,578 $— 
Payments—(3,250)(1,570)—
Change in fair value(5,488)(33)(8)—
Fair value at April 30, 2025$3,412 $2,697 $— $— 
Payments————
Transfers out of Level 3 (2)
(927)———
Change in fair value2,32177640—
Fair value at July 31, 2025$4,806 $2,774 $640 $— 
(1) The current portion of the contingent consideration liabilities balances of $0.6 million and $4.7 million as of July 31, 2025 and January 31, 2025, respectively, is included within accrued and other current liabilities. Changes in fair value of the contingent consideration liability for the Salo Sciences technical milestone payments are included within research and development expenses. Changes in fair value of the Salo Sciences contingent consideration liability for customer contract earnout payments are included within sales and marketing expenses. Changes in fair value of the contingent consideration liability for the Sinergise acquisition customer consent escrow payments are included within general and administrative expenses.
(2) During the three months ended July 31, 2025, the Company transferred 1,495,733 Private Placement Warrants from Level 3 to Level 1. The warrants were transferred to Level 1 due to the removal of the restrictive legends from the Private Placement Warrants, resulting in such warrants being able to be sold in the active market. The Company’s policy is to recognize transfers between fair value hierarchy levels at the beginning of the reporting period during which the transfer occurred.